Drug Utilization Review 1999 Index
December 1, 1999
Drug Utilization Review 1999 Index
Clinical pharmacy
New co-infection TB guidelines blast short-course, twice-weekly regimen, JAN:1
Is albumin-furosemide combo on the menu? JAN:10
Add tight lipid control to diabetes playbook, JAN:15
Studies boost hope for osteoporosis treatment, FEB:30
Somatostatin or Sandostatin? MAR:46
Beta-blockers rediscovered, gain primary role in cardiology, APR:49
Statewide stroke project achieves dramatic improvements in warfarin use, JUNE:81
Pharmacogenomics: Gene maps could offer direction for treatment, JULY:97
Seeing opportunities in specialization, pharmacists are turning to oncology, AUG:113
Inflammation not the main suspect in osteoarthritis, SEPT:133
RALES study brings good news about spironolactane, OCT:159
CHF drug therapy getting more complicated, OCT:161
Pharmacist interventions reduce drug errors by 66%, NOV:168
AHA, ACC update AMI guidelines, DEC:179
Medication use evaluations
Phenytoin monitoring in long-term care, JAN:5
Glucosamine sulfate for oesteoarthritis, JAN:7
Programming an automated system for wholesale orders, FEB:21
Assessment of empiric antimicrobial use in limiting resistance, FEB:24
Treating neuroleptic malignant syndrome, MAR:37
Preventing errors with antineoplastic agents, APR:53
Standardized insulin sliding scale, MAY:69
Cholestin used to treat hypercholesterolemia, MAY:71
Computer-generated medication profile review as replacement for automatic stop orders, JUNE:85
Quality assurance program monitors warfarin use, JUNE:88
Pharmacist review of discharge medication, JULY:101
Managing a primary-care dermatology clinic, JULY:105
Cardiology heparin dosing protocols, AUG:119
Thrombolytic therapy for acute MI, SEPT:137
Concomitant use of anxiolytic or sedative-hypnotic agents with SSRIs, OCT(suppl):1
Development, outcomes of ambulatory clinic for H. pylori, NOV(suppl):1
Whole-blood prothrombin time monitors, NOV(suppl):4
Assessing piperacillin/ tazobactam, DEC(suppl):1
COX-2 inhibitors, a review of prostaglandin pathway, DEC(suppl):3
Pharmacokinetics
Study: Albumin or PPF treatment can be deadly, JAN:11
New use for ipratropium: Pediatric emergencies, JAN:14
Sucrose suspected in cases of IVIG-associated renal failure, FEB:29
HIV research highlights conference on infections, MAY:79
ISMP issues error alert on new COX 2 inhibitor, JULY:100
INR superior to unadjusted PT in warfarin therapy, JULY:107
A drug for all addictions: Can science find the panacea addicts can't? OCT:149
Alcoholism: Newer drugs advancing treatment goals, OCT:152
Gender-specific health care new but growing, DEC:176
Significant drug-drug interactions with cisapride (Propulsid), DEC(suppl):8
Pharmacy practice
Pharmacy organizations merge on credentialing, JAN:4
Universal issues lead to pharmacist burnout, JAN:13
Coalition's white paper offers blueprint for pharmacy automation, FEB:17
Use technology to aid your compliance efforts, FEB:19
A day in the life of a clinical pharmacist, MAR:33
States seeking pharmacist reimbursement system, APR:61
PBM satisfaction up slightly, survey shows, APR:62
Is alternative medicine poised for hospital formularies? MAY:65
Computer systems fail to spot harmful interactions, MAY:79
Millennium resources, JUNE:93
IVIG shortage continues, JULY:110
New technology sparks confidentiality debate, AUG:117
Oversight plays catch-up to Internet pharmacy, AUG:127
Exterminating Y2K bugs: Contingency plan a must, SEPT:146
Hold the phone! Will tomorrow's telepharmacy be too complicated? NOV:165
Medication errors: selling the systems approach, DEC:173
Pharmacist counseling of at-risk Medicare patients, DEC:178
On-line giants merging, DEC(suppl):7
Regulation and accreditation
Viagra label warnings strengthened due to deaths, FEB:31
ISMP, FDA launch labeling education programs, MAY:78
FDA reprimands drug companies for ads, JUNE:84
New HEDIS measures, JUNE:94
Pharmacists hail OTC labeling inclusion, JUNE:95
FDA mandates trials in off-label regulations, JULY:100
HCFA reverses Medicaid ruling on serostim, JULY:109
Will pharmacy regulations be based on outcomes, JULY:109
Troglitazone to remain on shelves for now, AUG:116
Lisinopril: FDA considers approving higher doses, NOV:171